Abstract
In this issue of the Journal of Medicinal Chemistry, Janeba et al. found that the in vitro antiviral activity and selectivity index of the aryloxy phosphoramidate (ProTide) prodrug of the acyclic nucleoside phosphonate tenofovir (tenofovir alafenamide) can be dramatically improved by replacing the aryloxy pro-moiety with an appropriate tyrosine derivative. This Viewpoint highlights the possible impact and ramifications that these findings may have in the development of new ProTides.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
